288 related articles for article (PubMed ID: 35750038)
21. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
22. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Gluz O; Nitz U; Liedtke C; Christgen M; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Bangemann N; Lindner C; Kuemmel S; Clemens M; Potenberg J; Staib P; Kohls A; von Schumann R; Kates R; Kates R; Schumacher J; Wuerstlein R; Kreipe HH; Harbeck N
J Natl Cancer Inst; 2018 Jun; 110(6):628-637. PubMed ID: 29228315
[TBL] [Abstract][Full Text] [Related]
24. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
[TBL] [Abstract][Full Text] [Related]
25. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
26. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Røssevold AH; Andresen NK; Bjerre CA; Gilje B; Jakobsen EH; Raj SX; Falk RS; Russnes HG; Jahr T; Mathiesen RR; Lømo J; Garred Ø; Chauhan SK; Lereim RR; Dunn C; Naume B; Kyte JA
Nat Med; 2022 Dec; 28(12):2573-2583. PubMed ID: 36482103
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Hattori M; Masuda N; Takano T; Tsugawa K; Inoue K; Matsumoto K; Ishikawa T; Itoh M; Yasojima H; Tanabe Y; Yamamoto K; Suzuki M; Pan W; Cortes J; Iwata H
Cancer Med; 2023 May; 12(9):10280-10293. PubMed ID: 36916728
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
[TBL] [Abstract][Full Text] [Related]
29. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
30. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
[TBL] [Abstract][Full Text] [Related]
32. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
33. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Chisaki Y; Kuwada Y; Matsumura C; Yano Y
Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
[TBL] [Abstract][Full Text] [Related]
35. Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Liu Y; Fan L; Wang ZH; Shao ZM
Oncologist; 2023 Jan; 28(1):86-e76. PubMed ID: 36426808
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
Giuliani J; Mantoan B; Bonetti A
J Oncol Pharm Pract; 2021 Jul; 27(5):1245-1247. PubMed ID: 34018861
[TBL] [Abstract][Full Text] [Related]
37. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
[TBL] [Abstract][Full Text] [Related]
38. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.
Jiang Z; Ouyang Q; Sun T; Zhang Q; Teng Y; Cui J; Wang H; Yin Y; Wang X; Zhou X; Wang Y; Sun G; Wang J; Zhang L; Yang J; Qian J; Yan M; Liu X; Yi T; Cheng Y; Li M; Zang A; Wang S; Wang C; Wu X; Cheng J; Li H; Lin Y; Geng C; Gu K; Xie C; Xiong H; Wu X; Yang J; Li Q; Chen Y; Li F; Zhang A; Zhang Y; Wu Y; Nie J; Liu Q; Wang K; Mo X; Chen L; Pan Y; Fu P; Zhang H; Pang D; Sheng Y; Han Y; Wang H; Cang S; Luo X; Yu W; Deng R; Yang C; Keegan P
Nat Med; 2024 Jan; 30(1):249-256. PubMed ID: 38191615
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
Li J; Zhang T; Lu P; Zhao J; Chen L; Jiang J
Immunotherapy; 2020 Jul; 12(10):705-713. PubMed ID: 32522057
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
